Xenon Pharmaceuticals
XENE
291 hedge funds and large institutions have $5.8B invested in Xenon Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 74 funds opening new positions, 119 increasing their positions, 61 reducing their positions, and 33 closing their positions.
248% more capital inflows, than outflows
Capital inflows: $1.05B | Capital outflows: $302M
124% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 33
95% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 61
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
18% more funds holding
Funds holding: 246 → 291 (+45)
8% less call options, than puts
Call options by funds: $127M | Put options by funds: $138M
5.58% less ownership
Funds ownership: 109.22% → 103.64% (-5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
+$89.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$61.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$59.9M |
| 5 |
Deerfield Management
New York
|
+$49.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commodore Capital
New York
|
-$44.9M |
| 2 |
Braidwell
Stamford,
Connecticut
|
-$22.4M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$20.3M |
| 4 |
Millennium Management
New York
|
-$20M |
| 5 |
Barclays
London,
United Kingdom
|
-$16.7M |
XENE Hedge Fund Activity: Q1 2026 in Review
291 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2026, worth a combined $5.8B — up 53% from $3.78B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new XENE positions and 33 closed out — a net gain of 41 holders — while 119 added to existing stakes and 61 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $89.4M. The largest seller was Commodore Capital, cutting an estimated $44.9M.
- 291 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2026, up from 246 in Q4 2025.
- Funds reported $5.8B of Xenon Pharmaceuticals stock for Q1 2026, up 53% quarter-over-quarter.
- 74 funds opened new Xenon Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +41 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2026 was Polar Capital Holdings, an estimated $89.4M added.
- The largest Xenon Pharmaceuticals seller in Q1 2026 was Commodore Capital, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2026.